Rashida V. Orlova

Saint Petersburg, SPE 197022, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Complex Relationships Between Homologous Recombination Deficiency (HRD) Score and Mutational Status of Homologous Recombination Repair (HRR) Genes in Prostate Carcinomas.

Complex Relationships Between Homologous Recombination Deficiency (HRD) Score and Mutational Status of Homologous Recombination Repair (HRR) Genes in Prostate Carcinomas.

Journal: International journal of molecular sciences

Published: October 26, 2025

Maintenance avelumab in metastatic urothelial carcinoma: do tumour site and previous surgery matter?

Maintenance avelumab in metastatic urothelial carcinoma: do tumour site and previous surgery matter?

Journal: BJU international

Published: August 29, 2025

Clinical and Morphological Features of ER-Positive HER2-Negative Breast Tumors with PIK3CA Mutations in Russian Patients.

Clinical and Morphological Features of ER-Positive HER2-Negative Breast Tumors with PIK3CA Mutations in Russian Patients.

Journal: Cancers

Published: May 06, 2025

Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma.

Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma.

Journal: Exploration of targeted anti-tumor therapy

Published: December 04, 2024

Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study.

Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study.

Journal: Current oncology (Toronto, Ont.)

Published: November 19, 2024

Maintenance Therapy With Avelumab for Patients With Metastatic Urothelial Carcinoma: A Real-World, Ambispective RAVE-Bladder Study.

Maintenance Therapy With Avelumab for Patients With Metastatic Urothelial Carcinoma: A Real-World, Ambispective RAVE-Bladder Study.

Journal: Cancer medicine

Published: October 10, 2024

The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC.

The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: August 22, 2024

Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization

Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization

Journal: Arkhiv patologii

Published: June 05, 2023

Microsatellite instability and DNA mismatch repair deficiency detection in tumors of various sites

Microsatellite instability and DNA mismatch repair deficiency detection in tumors of various sites

Journal: Arkhiv patologii

Published: February 14, 2023

The predictive potential of autoimmune-inflammatory syndrome induced by adjuvants (ASIA) criteria to assess the risk of adverse events and efficacy of immune checkpoint inhibitor therapy.

The predictive potential of autoimmune-inflammatory syndrome induced by adjuvants (ASIA) criteria to assess the risk of adverse events and efficacy of immune checkpoint inhibitor therapy.

Journal: Immunologic research

Published: January 28, 2022

The Novel Diagnostic Index Based on HLA-DRB1 Genotype and PD-L1 Expression can Predict Severe irAEs in Patients with Metastatic Melanoma Taking Immune Checkpoint Inhibitors. The Results of the Pilot Study.

The Novel Diagnostic Index Based on HLA-DRB1 Genotype and PD-L1 Expression can Predict Severe irAEs in Patients with Metastatic Melanoma Taking Immune Checkpoint Inhibitors. The Results of the Pilot Study.

Journal: Critical reviews in immunology

Published: January 01, 2022

Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy.

Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy.

Journal: Cancer treatment and research communications

Published: December 21, 2021

Showing 1-12 of 33

Last Updated: 09/26/2026